帕博利珠单抗治疗复发性卵巢癌临床结局的分子决定因素:KEYNOTE-100探索性分析
该研究为II期KEYNOTE-100预设探索性分析,评估基因表达特征、肿瘤突变负荷(TMB)及多重免疫组化(mIHC)肿瘤微环境相关细胞表型与帕博利珠单抗治疗晚期复发性卵巢癌(ROC)临床结局的关联。结果显示基因表达特征与客观缓解率(ORR)无关联证据,TMB连续变量与结局无关;mIHC分析提示肿瘤区CD11c+及CD11c+/MHCII-/CD163-/CD68-髓系细胞表型密度与ORR正相关。
要点
- 基因表达特征与帕博利珠单抗治疗复发性卵巢癌的ORR无关联证据。
- TMB作为连续变量与ORR、PFS及OS均无显著关联(p>0.05)。
- 肿瘤区CD11c+及CD11c+/MHCII-/CD163-/CD68-髓系细胞密度与ORR正相关。
核心结论
- 该探索性分析在晚期复发性卵巢癌中未发现基因表达特征与帕博利珠单抗结局相关的证据。
- mIHC分析提示代表髓系细胞群的CD11c+和CD11c+/MHCII-/CD163-/CD68-表型可能与帕博利珠单抗改善结局相关。
研究设计与样本
- II期KEYNOTE-100研究的预设探索性分析,评估帕博利珠单抗治疗的晚期复发性卵巢癌患者。
- 可评估RNA测序数据者317例,全外显子测序数据者293例,可选mIHC数据者125例。
- 采用逻辑回归(ORR)和Cox比例风险回归(PFS;OS)评估基因表达特征、TMB及预设mIHC细胞表型密度作为连续变量与结局的关联。
- TcellinfGEP、TMB及mIHC细胞表型采用预设α=0.05单侧p值,非TcellinfGEP特征采用α=0.10;除TcellinfGEP和TMB外均进行多重性校正。
主要发现
- 未观察到ORR与基因表达关键轴之间的关联证据。
- 观察到结局与经TcellinfGEP校正的糖酵解特征(PFS,校正p=0.019;OS,校正p=0.085)及缺氧特征(PFS,校正p=0.064)呈负相关。
- TMB作为连续变量与结局无关(p>0.05)。
- 肿瘤区CD11c+和CD11c+/MHCII-/CD163-/CD68-髓系细胞表型密度与ORR呈正相关(校正p=0.025和0.013)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This prespecified exploratory analysis evaluated the association of gene expression signatures, tumor mutational burden (TMB), and multiplex immunohistochemistry (mIHC) tumor microenvironment-associated cell phenotypes with clinical outcomes of pembrolizumab in advanced recurrent ovarian cancer (ROC) from the phase II KEYNOTE-100 study. METHODS: Pembrolizumab-treated patients with evaluable RNA-sequencing (n = 317), whole exome sequencing (n = 293), or select mIHC (n = 125) data were evaluated. The association between outcomes (objective response rate [ORR], progression-free survival [PFS], and overall survival [OS]) and gene expression signatures (T-cell-inflamed gene expression profile [TcellinfGEP] and 10 non-TcellinfGEP signatures), TMB, and prespecified mIHC cell phenotype densities as continuous variables was evaluated using logistic (ORR) and Cox proportional hazards regression (PFS; OS). One-sided p-values were calculated at prespecified α = 0.05 for TcellinfGEP, TMB, and mIHC cell phenotypes and at α = 0.10 for non-TcellinfGEP signatures; all but TcellinfGEP and TMB were adjusted for multiplicity. RESULTS: No evidence of associations between ORR and key axes of gene expression was observed. Negative associations were observed between outcomes and TcellinfGEP-adjusted glycolysis (PFS, adjusted-p = 0.019; OS, adjusted-p = 0.085) and hypoxia (PFS, adjusted-p = 0.064) signatures. TMB as a continuous variable was not associated with outcomes (p > 0.05). Positive associations were observed between densities of myeloid cell phenotypes CD11c+ and CD11c+/MHCII-/CD163-/CD68- in the tumor compartment and ORR (adjusted-p = 0.025 and 0.013, respectively). CONCLUSIONS: This exploratory analysis in advanced ROC did not find evidence for associations between gene expression signatures and outcomes of pembrolizumab. mIHC analysis suggests CD11c+ and CD11c+/MHCII-/CD163-/CD68- phenotypes representing myeloid cell populations may be associated with improved outcomes with pembrolizumab in advanced ROC. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02674061.
引用
- Ledermann JA, Shapira-Frommer R, Santin AD, et al. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100. Gynecol Oncol. 2023. PMID: 37862791. doi:10.1016/j.ygyno.2023.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。